Shots:

• Accent to receive ~$446M including up front- pre-clinical- clinical- regulatory- and sales-based milestone along with royalties
• Ipsen obtains an exclusive license to develop- manufacture and commercialize a pre-clinical stage METTL3-inhibitor program
• The collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities to develop and commercialize transformative oncology medicines for the treatment of AML

  | Ref: Businesswire | Image: Pharma Boardroom